Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06159166 · ClinicalTrials.gov registry record · Phase 1
Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
A Phase 1 study of NF1 and Cutaneous Neurofibroma, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06159166 is a Phase 1 study of NF1 and Cutaneous Neurofibroma that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 24 participants, below the 76-participant average among 6 other NF1 trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06159166, a Phase 1 study of NF1 and Cutaneous Neurofibroma, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1/2a, open-label, non-randomized, multi-dose study of mirdametinib monotherapy in adults with NF1 and cNF. In both Phases of the study, participation in the study will comprise three periods: screening, treatment and post-study safety follow-up to be performed at the NF1 and cNF specialty center: Johns Hopkins University.
Conditions Studied
Interventions
- DRUG Mirdametinib
Study Locations (1)
Maryland
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-02-12 |
| Est. Completion | 2028-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06159166
The ClinicalTrials.gov registry entry for NCT06159166 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 76-participant average among 6 other NF1 trials with a reported enrollment target (68% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with NF1 appearing as the primary indexed condition, and to 1 intervention - of which Mirdametinib is the first listed.
NCT06159166 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06159166 about?
NCT06159166 is a clinical study titled "Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).". This is a Phase 1/2a, open-label, non-randomized, multi-dose study of mirdametinib monotherapy in adults with NF1 and cNF. In both Phases of the study, participation in the study will comprise three periods: screening, treatment and post-study safety follow-up to be performed at the NF1 and cNF spe...
What is the current status of trial NCT06159166?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-02-12. Estimated completion is 2028-11-15.
What conditions does trial NCT06159166 study?
This clinical trial studies the following conditions: NF1, Cutaneous Neurofibroma, Monotherapy.
What interventions are being tested in trial NCT06159166?
The interventions under investigation include: Mirdametinib (DRUG).
Who is sponsoring clinical trial NCT06159166?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06159166 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NF1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Avutometinib for People With Solid Tumor Cancers
RECRUITING · Phase 1
-
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
RECRUITING · Phase 1
-
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
ACTIVE NOT RECRUITING · Phase 1
-
Interventions for Reading Disabilities in NF1
ACTIVE NOT RECRUITING · Phase 2
-
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.